

Michel Ducreux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1748829/publications.pdf>

Version: 2024-02-01

285
papers

40,510
citations

4942

84
h-index

2617

194
g-index

300
all docs

300
docs citations

300
times ranked

33097
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 537-546.	1.2	12
2	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. <i>Digestive and Liver Disease</i> , 2022, 54, 324-330.	0.4	5
3	Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goals. <i>Annals of Palliative Medicine</i> , 2022, 11, 1876-1887.	0.5	5
4	Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancer. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	6
5	Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 599-608.	1.2	3
6	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 17-29.	3.7	307
7	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	1.4	2
8	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. <i>European Journal of Cancer</i> , 2021, 142, 147-149.	1.3	2
9	Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?. <i>Neuroendocrinology</i> , 2021, 111, 139-145.	1.2	3
10	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2023-2031.	0.8	4
11	Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2144-2150.	3.0	0
12	Future directions in drug development in pancreatic cancer. <i>Seminars in Oncology</i> , 2021, 48, 47-56.	0.8	10
13	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 401-409.	1.9	10
14	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , 2021, 53, 306-308.	0.4	8
15	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021, 150, 232-239.	1.3	11
16	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 991-1001.	5.1	179
17	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021, 153, 123-132.	1.3	25
18	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in FA@ration Francophone de Canc@rologie Digestive (FFCD) trials. <i>European Journal of Cancer</i> , 2021, 153, 40-50.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. <i>JCO Oncology Practice</i> , 2021, 17, e1311-e1317.	1.4	4
20	Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. <i>Future Oncology</i> , 2021, 17, 3343-3353.	1.1	2
21	Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4724.	1.7	18
22	Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors. <i>Digestive and Liver Disease</i> , 2021, 53, 1664-1665.	0.4	6
23	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. <i>Cancers</i> , 2021, 13, 5366.	1.7	17
24	Optimizing administration of third-line treatment in metastatic colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 24, 1-20.	0.3	0
25	Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 24, 6-11.	0.3	0
26	Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. <i>European Journal of Cancer</i> , 2020, 138, 89-98.	1.3	13
27	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	1.3	16
28	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	13.9	3,828
29	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. <i>European Journal of Cancer</i> , 2020, 135, 103-112.	1.3	11
30	5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. <i>European Journal of Cancer</i> , 2020, 129, 32-40.	1.3	12
31	Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
32	Gender medicine and oncology: report and consensus of an ESMO workshop. <i>Annals of Oncology</i> , 2019, 30, 1914-1924.	0.6	120
33	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	1.4	144
34	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. <i>European Journal of Cancer</i> , 2019, 123, 146-154.	1.3	46
35	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
36	Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. <i>Digestive and Liver Disease</i> , 2019, 51, 1185-1191.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. <i>Cancer Medicine</i> , 2019, 8, 2535-2544.	1.3	26
38	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2019, 112, 1-8.	1.3	23
39	Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 993-1002.	0.5	37
40	Vision loss after chemotherapy: an irinotecan-induced retinopathy. <i>European Journal of Cancer</i> , 2019, 112, 80-82.	1.3	5
41	Intestinal bacterial β -glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. , 2019, 199, 1-15.		59
42	Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 601-608.	0.7	1
43	5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. <i>Anti-Cancer Drugs</i> , 2019, 30, 313-317.	0.7	14
44	Adjuvant treatment of pancreatic cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 346-353.	1.1	23
45	Systemic treatment of pancreatic cancer revisited. <i>Seminars in Oncology</i> , 2019, 46, 28-38.	0.8	81
46	Cancer of the anal region. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 115-127.	2.0	40
47	MODUL ² a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1197-1204.	1.2	30
48	Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. <i>Nature Cell Biology</i> , 2018, 20, 296-306.	4.6	88
49	RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. <i>Digestive and Liver Disease</i> , 2018, 50, 507-512.	0.4	15
50	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	1.3	28
51	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. <i>Tumori</i> , 2018, 104, NP38-NP41.	0.6	1
52	Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index $\geq 10\%$: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE). <i>Neuroendocrinology</i> , 2018, 106, 38-46.	1.2	15
53	Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) – expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. <i>European Journal of Cancer</i> . 2018. 104. 91-103.	1.3	60
54	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. <i>European Journal of Cancer</i> , 2018, 98, 1-9.	1.3	30

#	ARTICLE	IF	CITATIONS
55	Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authorsâ€™ reply. <i>Digestive and Liver Disease</i> , 2018, 50, 974-975.	0.4	0
56	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. <i>Computational and Mathematical Methods in Medicine</i> , 2018, 2018, 1-8.	0.7	8
57	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. <i>European Journal of Cancer</i> , 2018, 100, 94-103.	1.3	20
58	Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial â€” PACHA-01 (NCT02494973). <i>BMC Cancer</i> , 2018, 18, 787.	1.1	22
59	Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2018, 50, 768-779.	0.4	73
60	Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-1). <i>Journal of Clinical Oncology</i> , 2018, 36, 1088-1095.	0.8	13
61	A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3110-TPS3110.	0.8	13
62	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4141-TPS4141.	0.8	38
63	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5-5.	0.8	19
64	Oxaliplatin desensitization after hypersensitivity reaction: A single-center experience on more than 300 procedures.. <i>Journal of Clinical Oncology</i> , 2018, 36, 610-610.	0.8	1
65	More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 40.	0.0	11
66	Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded). <i>Bulletin Du Cancer</i> , 2017, 104, 402-406.	0.6	14
67	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	2.7	33
68	Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?. <i>Lancet Oncology</i> , The, 2017, 18, 426-428.	5.1	3
69	The role of image-guided therapy in the management of colorectal cancer metastatic disease. <i>European Journal of Cancer</i> , 2017, 75, 231-242.	1.3	40
70	Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. <i>European Journal of Cancer</i> , 2017, 75, 259-267.	1.3	39
71	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2017, 79, 41-49.	1.3	43
72	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. <i>European Journal of Cancer</i> , 2017, 79, 15-22.	1.3	42

#	ARTICLE	IF	CITATIONS
73	Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. <i>European Journal of Cancer</i> , 2017, 81, 161-173.	1.3	27
74	Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). <i>Digestive and Liver Disease</i> , 2017, 49, 831-840.	0.4	53
75	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2017, 49, 568-571.	0.4	3
76	Leukocytosis and neutrophilia predicts outcome in anal cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 137-145.	0.3	50
77	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22
78	Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). <i>British Journal of Cancer</i> , 2017, 117, 965-973.	2.9	18
79	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	0.7	25
80	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer—A definite conclusion?. <i>Seminars in Oncology</i> , 2017, 44, 129-131.	0.8	3
81	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	1.3	120
82	Are we reproducible in measurement of NET liver metastasis?. <i>Digestive and Liver Disease</i> , 2017, 49, 1121-1127.	0.4	5
83	Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. <i>Neuroendocrinology</i> , 2017, 105, 26-34.	1.2	11
84	Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. <i>Investigational New Drugs</i> , 2017, 35, 247-249.	1.2	8
85	Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). <i>Clinical Colorectal Cancer</i> , 2017, 16, 129-140.e4.	1.0	12
86	Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 9-16.	1.1	12
87	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	466
88	Fatigue and health behaviors in cancer survivors: A cross-sectional population based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10069-10069.	0.8	1
89	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3520-3520.	0.8	2
90	Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3567-3567.	0.8	3

#	ARTICLE	IF	CITATIONS
91	EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM).. Journal of Clinical Oncology, 2017, 35, TPS3633-TPS3633.	0.8	1
92	Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget, 2017, 8, 11579-11588.	0.8	36
93	Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial) Tj ETQq1 1 0.784314 0.8 0.1 / Overflock 10	0.8	0
94	Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000â€“05 Trial. Biometrics, 2016, 72, 907-916.	0.8	28
95	Treatment sequence of synchronously (liver) metastasized colon cancer. Digestive and Liver Disease, 2016, 48, 1119-1123.	0.4	15
96	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
97	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	1.3	78
98	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. European Journal of Cancer, 2016, 66, 75-82.	1.3	5
99	Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?. European Journal of Cancer, 2016, 69, 178-179.	1.3	2
100	Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer, 2016, 68, 163-172.	1.3	8
101	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	1.3	73
102	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. Hepatic Oncology, 2016, 3, 109-118.	4.2	4
103	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Digestive and Liver Disease, 2016, 48, 441-445.	0.4	17
104	The development of new agents and molecular classifications. Nature Reviews Clinical Oncology, 2016, 13, 69-70.	12.5	21
105	Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 2016, 57, 10-22.	1.3	138
106	Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.. Journal of Clinical Oncology, 2016, 34, 3532-3532.	0.8	1
107	Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study.. Journal of Clinical Oncology, 2016, 34, TPS785-TPS785.	0.8	1
108	Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO).. Journal of Clinical Oncology, 2016, 34, 4030-4030.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Impact of early tumor response on prognostic of patients with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab after failure of systemic chemotherapy (European Phase II OPTILIV).. Journal of Clinical Oncology, 2016, 34, e15036-e15036.	0.8	0
110	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. Journal of Clinical Oncology, 2016, 34, TPS4148-TPS4148.	0.8	0
111	Prognostic Similarities and Differences in Optimally Resected Liver Metastases and Peritoneal Metastases From Colorectal Cancers. Annals of Surgery, 2015, 261, 157-163.	2.1	68
112	GEP-NETS UPDATE: Interventional radiology: role in the treatment of liver metastases from GEP-NETS. European Journal of Endocrinology, 2015, 172, R151-R166.	1.9	109
113	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treatment Reviews, 2015, 41, 129-135.	3.4	14
114	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. Current Colorectal Cancer Reports, 2015, 11, 78-83.	1.0	0
115	Evaluating iatrogenic prescribing: Development of an oncology-focused trigger tool. European Journal of Cancer, 2015, 51, 427-435.	1.3	15
116	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. European Journal of Cancer, 2015, 51, 327-339.	1.3	63
117	Body-mass index, cancer, and implications for screening. Lancet Oncology, The, 2015, 16, e102-e103.	5.1	5
118	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	6.0	367
119	Analysis of KRAS and NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5469-5479.	3.2	152
120	Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. European Journal of Cancer, 2015, 51, 166-176.	1.3	105
121	Predisposing Factors of Liver Necrosis after Transcatheter Arterial Chemoembolization in Liver Metastases from Neuroendocrine Tumor. CardioVascular and Interventional Radiology, 2015, 38, 372-380.	0.9	29
122	IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703.. Journal of Clinical Oncology, 2015, 33, TPS791-TPS791.	0.8	8
123	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	0.8	22
124	Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14619-e14619.	0.8	0
125	Imagine a world without cancer. BMC Cancer, 2014, 14, 186.	1.1	12
126	A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases. Annals of Surgical Oncology, 2014, 21, 2052-2058.	0.7	52

#	ARTICLE	IF	CITATIONS
127	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. <i>Clinical Cancer Research</i> , 2014, 20, 265-272.	3.2	36
128	Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 107-116.	0.6	182
129	Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial. <i>European Journal of Cancer</i> , 2014, 50, 3098-3106.	1.3	69
130	Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial. <i>European Journal of Cancer</i> , 2014, 50, 3107-3115.	1.3	82
131	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , 2014, 50, 2983-2993.	1.3	56
132	Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. <i>Investigational New Drugs</i> , 2014, 32, 1028-1035.	1.2	21
133	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. <i>Digestive and Liver Disease</i> , 2014, 46, 950-955.	0.4	5
134	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 819-828.	5.1	345
135	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3568.	0.8	53
136	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA387-LBA387.	0.8	24
137	Current use and attitudes toward the use of information technologies in health care among cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20652-e20652.	0.8	0
138	Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3593-3593.	0.8	6
139	Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3589-3589.	0.8	1
140	Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitor of the response.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3638-3638.	0.8	0
141	Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15253-e15253.	0.8	0
142	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2565-2565.	0.8	0
143	A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial. <i>Annals of Surgical Oncology</i> , 2013, 20, 4289-4297.	0.7	80
144	The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer. <i>Current Oncology Reports</i> , 2013, 15, 182-189.	1.8	85

#	ARTICLE	IF	CITATIONS
145	Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action. <i>Cancer Treatment Reviews</i> , 2013, 39, 592-601.	3.4	104
146	Improving outcomes in colorectal cancer: Where do we go from here?. <i>European Journal of Cancer</i> , 2013, 49, 2476-2485.	1.3	43
147	Bevacizumab and Subtype-Adapted Chemotherapy Backbone in Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2013, 31, 976-977.	0.8	5
148	Are G3 ENETS neuroendocrine neoplasms heterogeneous?. <i>Endocrine-Related Cancer</i> , 2013, 20, 649-657.	1.6	275
149	Frequency and characterization of gastroenteropancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. <i>Endocrine-Related Cancer</i> , 2013, 20, 229-239.	1.6	11
150	Reply to R. Glynne-Jones et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 165-166.	0.8	2
151	Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases in Patients at High Risk of Hepatic Recurrence. <i>Annals of Surgery</i> , 2013, 257, 114-120.	2.1	76
152	Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy?. <i>Annals of Surgery</i> , 2013, 257, 1065-1071.	2.1	219
153	Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?. <i>OncoTargets and Therapy</i> , 2013, 6, 95.	1.0	2
154	Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV). <i>Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 3</i>	0.8	2
155	Value of cardiophrenic angle lymph nodes for the diagnosis of colorectal peritoneal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 372-372.	0.8	0
156	Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2012, 17, 1063-1072.	1.9	112
157	Chemotherapy for colorectal cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e4.	5.1	0
158	Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1941-1948.	0.8	305
159	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. <i>Journal of Hepatology</i> , 2012, 56, 609-617.	1.8	161
160	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012, 48, 2941-2953.	1.3	129
161	Serum Gamma-Glutamyl-Transferase Independently Predicts Outcome After Transarterial Chemoembolization of Hepatocellular Carcinoma: External Validation. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1102-1108.	0.9	25
162	Intervention in gastro-enteropancreatic neuroendocrine tumours. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 855-865.	1.0	16

#	ARTICLE	IF	CITATIONS
163	Traitement systématique des cancers biliaires avancés : présent et futur. <i>Cancer Digest</i> , 2012, , .	0.0	0
164	mTOR as a therapeutic target in patients with gastric cancer. <i>International Journal of Cancer</i> , 2012, 130, 491-496.	2.3	84
165	Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4036-4036.	0.8	8
166	Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4071-4071.	0.8	12
167	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 387-387.	0.8	9
168	Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study. <i>Journal of Geriatric Oncology</i> , 2011, 2, 105-111.	0.5	3
169	Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD) Tj ETQq1 1 0,784314 rBT /Over 5.1 128	0.7	11
170	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1817-1825.	13.9	6,140
171	Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study. <i>International Journal of Biological Markers</i> , 2011, 26, 94-101.	0.7	38
172	Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome. <i>Annals of Surgery</i> , 2011, 254, 114-118.	2.1	30
173	Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis. <i>Annals of Surgery</i> , 2011, 254, 289-293.	2.1	206
174	Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. <i>Radiation Oncology</i> , 2011, 6, 124.	1.2	11
175	Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX6) as first-line treatment for metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2011, 128, 682-690.	2.3	131
176	Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (>10%) Well-Differentiated Endocrine Carcinoma Staging. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 665-671.	1.8	93
177	Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results. <i>Radiology</i> , 2011, 258, 291-300.	3.6	201
178	Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?. <i>Digestive Surgery</i> , 2011, 28, 114-120.	0.6	49
179	Prolonged Survival of Initially Unresectable Hepatic Colorectal Cancer Patients Treated With Hepatic Arterial Infusion of Oxaliplatin Followed by Radical Surgery of Metastases. <i>Annals of Surgery</i> , 2010, 251, 686-691.	2.1	116
180	Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 1010-1023.	0.7	37

#	ARTICLE	IF	CITATIONS
181	Immunogenic death of colon cancer cells treated with oxaliplatin. <i>Oncogene</i> , 2010, 29, 482-491.	2.6	937
182	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4706-4713.	0.8	909
183	Percutaneous Femoral Implantation of an Arterial Port Catheter for Intraarterial Chemotherapy: Feasibility and Predictive Factors of Long-term Functionality. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1681-1688.	0.2	62
184	Biliary cancers, chemotherapy, and cetuximab. <i>Lancet Oncology</i> , The, 2010, 11, 1110-1112.	5.1	1
185	Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCO 2000-05. <i>Journal of Clinical Oncology</i> , 2010, 28, 2556-2564.	0.8	146
186	Abstract 4154: Intratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patients' management. , 2010, , .		0
187	Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?. <i>Journal of Clinical Oncology</i> , 2009, 27, 1829-1835.	0.8	514
188	A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). <i>Annals of Oncology</i> , 2009, 20, 674-680.	0.6	189
189	Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. <i>Endocrine-Related Cancer</i> , 2009, 16, 585-597.	1.6	105
190	Mutational status of <i>EGFR</i> , <i>BRAF</i> , <i>PI3KCA</i> and <i>JAK2</i> genes in endocrine tumors. <i>International Journal of Cancer</i> , 2009, 124, 751-753.	2.3	14
191	Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 749-752.	1.2	21
192	The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2009, 17, 1255-1261.	1.0	17
193	Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5924-5930.	0.8	645
194	Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008. <i>Clinical and Experimental Gastroenterology</i> , 2009, 2, 13.	1.0	0
195	Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure. <i>Annals of Surgical Oncology</i> , 2008, 15, 219-226.	0.7	168
196	<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 374-379.	0.8	1,398
197	High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?. <i>Oncology</i> , 2008, 74, 17-24.	0.9	16
198	Benefits of Contrast-Enhanced Sonography for the Detection of Liver Lesions: Comparison with Histologic Findings. <i>American Journal of Roentgenology</i> , 2008, 190, 683-690.	1.0	55

#	ARTICLE	IF	CITATIONS
199	Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal Carcinomatosis. <i>Annals of Surgery</i> , 2008, 247, 445-450.	2.1	136
200	Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology). , 2008, , 13-21.		0
201	CA 19-9 and Pancreatic Carcinoma, a Revival?. <i>Oncology Research and Treatment</i> , 2007, 30, 12-13.	0.8	2
202	Cetuximab plus Gemcitabine-Oxaliplatin (GEMOX) in Patients with Refractory Advanced Intrahepatic Cholangiocarcinomas. <i>Oncology</i> , 2007, 72, 105-110.	0.9	96
203	Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4593-4602.	0.8	183
204	Complete, Long-Standing Regression of Hepatocellular Carcinoma After Somatostatin Analogue Treatment. <i>Journal of Clinical Oncology</i> , 2007, 25, e15-e16.	0.8	7
205	Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). <i>Cancer</i> , 2007, 109, 1384-1390.	2.0	187
206	Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. <i>Cancer</i> , 2007, 110, 265-274.	2.0	63
207	Pancreatic cancer: From pathogenesis to cure. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 997-1014.	1.0	11
208	Treatment of Advanced Pancreatic Cancer. <i>Seminars in Oncology</i> , 2007, 34, S25-S30.	0.8	57
209	Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 281-285.	0.9	22
210	Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin. <i>Annals of Surgical Oncology</i> , 2007, 14, 3188-3194.	0.7	125
211	KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. <i>Cancer Research</i> , 2006, 66, 3992-3995.	0.4	2,116
212	Splenic infarction and bevacizumab. <i>Lancet Oncology</i> , The, 2006, 7, 1038.	5.1	11
213	Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level. <i>European Journal of Cancer</i> , 2006, 42, 456-459.	1.3	62
214	Thyroid metastases from colorectal cancer: The Institut Gustave Roussy experience. <i>European Journal of Cancer</i> , 2006, 42, 1756-1759.	1.3	37
215	Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer. <i>Oncology</i> , 2006, 71, 40-48.	0.9	3
216	Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1471-1478.	0.4	65

#	ARTICLE	IF	CITATIONS
217	Usefulness of Guiding Needles for Radiofrequency Ablative Treatment of Liver Tumors. CardioVascular and Interventional Radiology, 2006, 29, 650-654.	0.9	24
218	Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Gastroenterologie Clinique Et Biologique, 2006, 30, 357-363.	0.9	35
219	Peritoneal carcinomatosis of colorectal origin. Gastroenterologie Clinique Et Biologique, 2006, 30, 1200-1204.	0.9	95
220	Midterm Local Efficacy and Survival after Radiofrequency Ablation of Lung Tumors with Minimum Follow-up of 1 Year: Prospective Evaluation. Radiology, 2006, 240, 587-596.	3.6	347
221	Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCO 9203. Journal of Clinical Oncology, 2006, 24, 4620-4625.	0.8	1,551
222	Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCO 9404 randomised trial). Anticancer Research, 2006, 26, 3877-83.	0.5	10
223	Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery, 2005, 137, 411-416.	1.0	72
224	Ex Vivo Sentinel Lymph Node Study For Rectal Adenocarcinoma: Preliminary Study. World Journal of Surgery, 2005, 29, 1166-1170.	0.8	26
225	Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Journal of Clinical Oncology, 2005, 23, 4881-4887.	0.8	215
226	ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6212-6217.	3.2	224
227	Artificially Induced Pneumothorax for Percutaneous Transthoracic Radiofrequency Ablation of Tumors in the Hepatic Dome: Initial Experience. Radiology, 2005, 236, 666-670.	3.6	56
228	Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging. Journal of Clinical Oncology, 2005, 23, 70-78.	0.8	339
229	Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCO randomized phase III trial (8801). Annals of Oncology, 2005, 16, 1488-1497.	0.6	138
230	Antitumoral Effect of Celecoxib in Hepatocellular Carcinoma. Journal of Clinical Oncology, 2005, 23, 4805-4806.	0.8	13
231	Combination Chemotherapy in Advanced Small Bowel Adenocarcinoma. Oncology, 2005, 69, 290-294.	0.9	81
232	Malignant Gastroduodenal Obstruction: Palliation with Self-expanding Metallic Stents. Journal of Vascular and Interventional Radiology, 2005, 16, 247-253.	0.2	91
233	Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study. European Journal of Cancer, 2005, 41, 2861-2867.	1.3	17
234	Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect. Annals of Surgical Oncology, 2005, 12, 900-909.	0.7	240

#	ARTICLE	IF	CITATIONS
235	Simultaneous decompression colonoscopy and radiologic G-tube insertion in a patient with megacolon because of chronic colonic pseudo-obstruction. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 975-976.	0.5	11
236	Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. <i>Neuroendocrinology</i> , 2004, 80, 244-251.	1.2	152
237	Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. <i>Annals of Oncology</i> , 2004, 15, 1558-1565.	0.6	114
238	Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease. <i>Annals of Surgical Oncology</i> , 2004, 11, 274-280.	0.7	161
239	Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. <i>Journal of Surgical Oncology</i> , 2004, 86, 4-9.	0.8	94
240	Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. <i>Surgical Clinics of North America</i> , 2004, 84, 607-625.	0.5	18
241	An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. <i>Human Pathology</i> , 2004, 35, 1564-1567.	1.1	13
242	Biliary tract neoplasms: update 2003. <i>Current Opinion in Oncology</i> , 2004, 16, 364-371.	1.1	27
243	Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. <i>Anti-Cancer Drugs</i> , 2004, 15, 647-650.	0.7	81
244	Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. <i>European Radiology</i> , 2003, 13, 136-140.	2.3	235
245	Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. <i>Cancer</i> , 2003, 98, 2664-2670.	2.0	71
246	Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. <i>Surgery</i> , 2003, 133, 375-382.	1.0	212
247	MR Imaging of Hepatic Metastases Caused by Neuroendocrine Tumors: Comparing Four Techniques. <i>American Journal of Roentgenology</i> , 2003, 180, 121-128.	1.0	172
248	Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. <i>Cancer Research</i> , 2003, 63, 5738-44.	0.4	179
249	Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction. <i>Journal of Clinical Oncology</i> , 2002, 20, 4303-4312.	0.8	104
250	Percutaneous Radiofrequency Ablation of Hepatic Tumors During Temporary Venous Occlusion. <i>American Journal of Roentgenology</i> , 2002, 178, 53-59.	1.0	190
251	Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. <i>Annals of Oncology</i> , 2002, 13, 267-272.	0.6	317
252	Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. <i>Annals of Oncology</i> , 2002, 13, 721-729.	0.6	67

#	ARTICLE	IF	CITATIONS
253	A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1185-1191.	0.6	113
254	Hepatic Tumors Treated with Percutaneous Radio-frequency Ablation: CT and MR Imaging Follow-up. <i>Radiology</i> , 2002, 223, 255-262.	3.6	303
255	Cancer of the anal region. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 77-92.	2.0	42
256	During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. <i>British Journal of Surgery</i> , 2002, 86, 784-788.	0.1	317
257	Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. <i>Cancer</i> , 2001, 92, 71-76.	2.0	390
258	Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 2648-2657.	0.8	522
259	Treatment of carcinoid syndrome. , 2000, 88, 770-776.		240
260	Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2293-2300.	0.8	61
261	Phase I and Pharmacokinetic Study of the Camptothecin Analog DX-8951f Administered as a 30-Minute Infusion Every 3 Weeks in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3986-3992.	0.8	18
262	Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 3545-3552.	0.8	36
263	The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. <i>American Journal of Gastroenterology</i> , 2000, 95, 3276-3281.	0.2	184
264	Radiofrequency Ablation of 100 Hepatic Metastases with a Mean Follow-Up of More Than 1 Year. <i>American Journal of Roentgenology</i> , 2000, 175, 1619-1625.	1.0	371
265	Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2901-2901.	0.8	94
266	Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 69-75.	1.8	45
267	Hepatic Intraarterial ¹³¹ Iodized Oil for Treatment of Hepatocellular Carcinoma in Patients with Impeded Portal Venous Flow. <i>Radiology</i> , 1999, 212, 665-668.	3.6	31
268	Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. <i>British Journal of Cancer</i> , 1999, 81, 1351-1355.	2.9	455
269	Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. <i>Journal of the American College of Surgeons</i> , 1998, 187, 487-493.	0.2	193
270	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. , 1998, 69, 88-93.		122

#	ARTICLE	IF	CITATIONS
271	Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. <i>Annals of Thoracic Surgery</i> , 1998, 66, 214-218.	0.7	185
272	Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. <i>Journal of Hepatology</i> , 1998, 29, 129-134.	1.8	384
273	Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. <i>Annals of Oncology</i> , 1998, 9, 653-656.	0.6	141
274	Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2739-2744.	0.8	273
275	Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg. <i>Tumori</i> , 1998, 84, 335-347.	0.6	14
276	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. , 1998, 69, 88.		4
277	Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase II study. <i>Radiotherapy and Oncology</i> , 1997, 45, 129-132.	0.3	14
278	Accelerated fractionation in esophageal cancers: A multivariate analysis on 88 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 1013-1018.	0.4	33
279	Abdominoperineal resection combined with pre- and postoperative radiation therapy in the treatment of low-lying rectal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 59-65.	0.4	9
280	Surgery for lung metastases from colorectal cancer: analysis of prognostic factors.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2047-2053.	0.8	194
281	Liver abscess formation after local treatment of liver tumors. <i>Hepatology</i> , 1996, 23, 1436-1440.	3.6	112
282	Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.. <i>Gut</i> , 1996, 39, 279-283.	6.1	181
283	Diagnosis, and prognosis of AIDS-related cholangitis. <i>Aids</i> , 1995, 9, 875-880.	1.0	61
284	Transcatheter chemoembolization of progressive carcinoid liver metastasis.. <i>Radiology</i> , 1993, 189, 541-547.	3.6	174
285	Management of malignant hilar biliary obstruction by endoscopy results and prognostic factors. <i>Digestive Diseases and Sciences</i> , 1992, 37, 778-783.	1.1	124